Kiener Peter A Form 3/A September 09, 2005

## FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

Expires:

response...

January 31, 2005

0.5

Estimated average burden hours per

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

**SECURITIES** 

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person 2. Date of Event 3. Issuer Name and Ticker or Trading Symbol Requiring Statement MEDIMMUNE INC /DE [MEDI] Kiener Peter A (Month/Day/Year) 05/19/2005 (Last) (First) (Middle) 4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year) C/O MEDIMMUNE, INC., ONE 05/31/2005 (Check all applicable) **MEDIMMUNE WAY** (Street) 6. Individual or Joint/Group 10% Owner Director \_X\_\_ Officer Other Filing(Check Applicable Line) (give title below) (specify below) \_X\_ Form filed by One Reporting SVP, Research Person GAITHERSBURG, MDÂ 20878 Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned 4. Nature of Indirect Beneficial 1. Title of Security 2. Amount of Securities Beneficially Owned Ownership Ownership (Instr. 4) (Instr. 4) Form: (Instr. 5) Direct (D) or Indirect (I) (Instr. 5) Reminder: Report on a separate line for each class of securities beneficially SEC 1473 (7-02) owned directly or indirectly. Persons who respond to the collection of

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

information contained in this form are not required to respond unless the form displays a

currently valid OMB control number.

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of	5. Ownership Form of Derivative	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security	Security: Direct (D) or Indirect (I)	

						(Instr. 5)	
Stock Option (Right to buy)	(1)	03/04/2014	Common Stock	30,000	\$ 23.45	D	Â
Stock Option (Right to buy)	(1)	02/15/2015	Common Stock	55,000	\$ 24.17	D	Â
Stock Option (Right to buy)	(1)	02/20/2013	Common Stock	30,000	\$ 29.34	D	Â
Stock Option (Right to buy)	(1)	09/01/2013	Common Stock	5,000	\$ 34.7	D	Â
Stock Option (Right to buy)	(1)	09/05/2011	Common Stock	30,000	\$ 40.85	D	Â
Stock Option (Right to buy)	(1)	02/21/2012	Common Stock	11,500	\$ 41.41	D	Â

## **Reporting Owners**

Reporting Owner Name / Address	Relationships					
· · · · · · · · · · · · · · · · · · ·	Director	10% Owner	Officer	Othe		
Kiener Peter A						
C/O MEDIMMUNE, INC.	â	â	SVP, Research	â		
ONE MEDIMMUNE WAY	A	A	A SVP, Research	A		
GAITHERSBURG Â MDÂ 20878						

## **Signatures**

William C. Bertrand, Jr., as attorney-in-fact 09/09/2005

\*\*Signature of Reporting Person Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Grant exercisable in quarterly installments over a four year period.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2